KR890009911A - 7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린 카르복실산의 유도체, 그의 제조방법 및 제약학적 조성물 - Google Patents

7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린 카르복실산의 유도체, 그의 제조방법 및 제약학적 조성물 Download PDF

Info

Publication number
KR890009911A
KR890009911A KR1019880017747A KR880017747A KR890009911A KR 890009911 A KR890009911 A KR 890009911A KR 1019880017747 A KR1019880017747 A KR 1019880017747A KR 880017747 A KR880017747 A KR 880017747A KR 890009911 A KR890009911 A KR 890009911A
Authority
KR
South Korea
Prior art keywords
azetidinyl
oxo
dihydro
difluoro
cyclopropyl
Prior art date
Application number
KR1019880017747A
Other languages
English (en)
Other versions
KR920004136B1 (ko
Inventor
후안 빠레스 꼬로미나스
호르디 후리골라 꼰스딴사
아우구스또 꼴롬보 삐눌
Original Assignee
마뇨사스 바레라, 앤리께
라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8718289A external-priority patent/FR2625200A1/fr
Application filed by 마뇨사스 바레라, 앤리께, 라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마 filed Critical 마뇨사스 바레라, 앤리께
Publication of KR890009911A publication Critical patent/KR890009911A/ko
Application granted granted Critical
Publication of KR920004136B1 publication Critical patent/KR920004136B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린 카르복실산의 유도체, 그의 제조방법 및 제약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(Ⅰ)의 신규한 헤테로 로리형 화합물 :
    상기식에서, R1은 저급알케닐 또는 알킬라디칼, 할로알킬 라디칼, 시클로알킬 라디칼, 아미노알킬 라디칼, 아릴 아디칼 또는 치환된 아릴라디칼, 특히 1개 이상의 불소원자 치환체를 갖는 라디칼을 나타내고 : R2는 수소원자, 할로겐원자를 나타내거나, R1과 R2가 함께 X기를 형성할 수도 있으며 : R3는 수소원자 또는 저급알킬 라디칼을 나타내고 : R4와 R5와 R6는 독립적으로 수소원자, 저급알킬 라디칼, 히드록시 라디탈, 아미노 라디칼, 아미노알킬 라디칼, 알킬아미노 라디칼, 디알킬아미노 라디칼, 알킬아미노알킬 라디칼, 알콕시 라디칼, 메실옥시라디칼, 히드록시알킬 라디칼, 시아노 라디칼, 아실아미노알킬 라디칼, 카르복실 라디칼, 카르복스 아미도 라디칼, 카르복시알킬 라디칼, 할로겐 원자, 알킬카르복시 라디칼, 예컨대 아세톡시, 아세트아미도 라디칼 또는 아세트아미도알킬 라디칼(이들 마지박 두 라디칼에 있어서, 말단 자유 알킬기는 불소화될 수 있고, 아세트아미도알킬 라디칼내의 질소원자는 알킬치환체를 가질 수 있다)을 나타내고 ; X는 -CH2-CH2-
    R7은 수소원자, 또는 저급알킬 라디칼을 나타내고 ; R8은 수소원자, 또는 할로겐원자를 나타내며 ; Y는 CH 또는 N을 나타내고 ; 단, R1및 R2가 함께 -O-CH2-CH(CH3)-로 표시되는 연결기를 형성하고, R3,R4및 R6가 수소원자를 나타내고, R5가 히드록시라디칼(OH) 또는 히드록시메틸 라디칼(CH2OH)을 나타내는 일반식(Ⅰ)의 화합물과, R1이 에틸라디칼을 나타내고, R2가 불소원자를 나타내고, R3,R4및 R6가 수소원자를 나타내며 R5가 에틸아미노메틸 라디칼(CH3CH2NHCH2)을 나타내는 일반식(Ⅰ)의 화합물은 제외된다.
  2. 제1항에 있어서, R6및 R3가 수소원자를 나타내고 R1,R2,R4및 R5가 앞서 정의한 바와 같은 의미를 갖는 일반식(Ⅰ)의 상응함을 특징으로 하는 헤테로고리형 화합물.
  3. 제1항 또는 제2항에 있어서, R2,R4및 R5가 앞서 정의한 바와같은 의미를 갖는 하기 일반식(Ia)에 상응함을 특징으로 하는 헤테로고리형 화합물 :
  4. 제1항 또는 제2항에 있어서, 1-(4-플루오로페닐)-6.8-디플루오로-7-(3-메틸-3-트리플루오로아세트아미도-1-아제티디닐)-1,4-디히드로-4-옥소-3-3-퀴놀린카르복실산, 1-(4-플루오로페닐)-6, 8-디플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(에틸-6,8-디플루오로-1,4-디히드로-4-옥소-7-(3-메틸-3-트리플루오로아세트아미도-1-아제티디닐)-3-퀴놀린카르복실산, 1-에틸-6,8-디플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1, 4-디히드로-4-옥소-3-퀴놀린카르복실산, [S]-(-)-9-플루오로-3-메틸-7-옥소-2,3-디히드로-7H-피리도[1,2,3,-데][1,4]벤즈옥사진-10-(3-아미노-3-메틸-1-아제티디닐)-6-카르복실산, [R]-(+)-9-플루오로-3-메틸-7-옥소-2,3-디히드로-7H-피리도[1,2,3-데][1,4]벤즈옥사진-10-(3-아미노-3-메틸-1-아제티디닐)-6 카르복실산, 1-에틸-6-플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(2-플루오로메틸)-6-플루오로-7-(3-메틸-3-아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(2,4-디플루오로페닐)-6-플루오로-7-(3-메틸-3-아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(2-플루오로에틸)-6,8-디플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(4-플루오로페닐)-6-플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-(2,4-디플루오로페닐)-6,8-디플루오로-7-(3-메틸-3-트리플루오로아세트아미도-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복시산, 1-(2,4-디플루오로페닐)-6,8-디플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복시산으로 부터 선택된 일반식(Ⅰ)의 화합물.
  5. 제1항, 제2항 또는 제3항에 있어서, 에틸 1-시클로프로필-6,8-디플루오로-7-(3-히드록시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실레이트, 1-시클로프로필-6,8-디플루오로-7-(3-히드록시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 에틸 1-시클로프로필-6,8-디플루오로-7-(3-메실옥시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실레이트, 에틸 7-(3-아세틸아미노메틸-1-아제티디닐)-1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실레이트, 1-시클로프로필-6,8-디플루오로-7-(3-카르복시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-사이노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-사이노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-메틸-3-히드록시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 7-(3-트리플루오로아세트아미도메틸-1-아제티디닐)-1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 7-(3-아미노메틸-1-아제티디닐)-1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-메실옥시-1-아제티디닐]-6,8-디플루오로-1,4-디히드로-1-시클로프로필-4-옥소-3-퀴놀린카르복실산, 7-(3-N'-에틸아미노메틸-1-아제티디닐)-6,8-디플루오로-1,4-디히드로-1-시클로프로필-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-1,4-디히드로-7-(1-1-아제티디닐)-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7(3-메틸-3-트리플루오로아세트아미도-1-아제티디닐)-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-1,4-디히드로-7-(3-메틸-3-아메노-1-아제티디닐)-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(아세톡시-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-히드록시-1-아제티디닐(-1,4-디히드로-4-옥소-3-퀴놀린카르복실실산, 1-시클로프로필-6,8-디플루오로-7-(3-아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7(3-트리플루오로아세트아미도메틸-3-메틸-3-메틸-1-아제티디닐(-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-트리플루오로아세트아미도에틸아미노메틸-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-아메노메틸-3-메틸-1-아제티디닐)-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-에틸아미노메틸-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-7-(3-메틸-3-N,N-디메틸아미노-1-아제티디닐)-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-디메틸아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-디메틸아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6,8-디플루오로-7-(3-아미노-3-메틸-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 히드로클로라이드, 1-시클로프로필-6,8-디플루오로-7-(3-메틸ㅇ미노-1-아제티디닐-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 1-시클로프로필-6-플루오로-7-(3-아미노-1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산, 으로부터 선택되는 일반식(Ⅰ)의 화합물.
  6. 하기 일반식(Ⅱ)의 헤테로고리형 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시킴을 특징으로 하는, 제1항 내지 제5항중 어느 한항에 따른 일반식(Ⅰ)의 유도체의 제조방법.
    상기식에서 R1,R2및 R3는 앞서 정의한 바와같은 의미를 가지며, Z은 할로겐원자를 나타낸다.
    상기식에서, R4,R5및 R6는 앞서 정의한 바와같은 의미를 갖는다.
  7. 하기 일반식(Ⅱ)의 헤테로고리형 화합물을 하기 일반식(Ⅳ)의 화합물과 반응시킴을 특징으로 하는 제1항 내지 제5항중 어느 한항에 따른 일반식(Ⅰ)의 유도체인 제조방법 :
    상기식에서 R1,R2및 R3는 앞서 정의한 바와같은 의미를 가지며, Z은 아미노라디칼을 나타낸다.
    상기식에서, R4,R5및 R6는 앞서 정의한 바와같은 의미를 가지며, A는 할로겐원자, 히드록실 라디칼, 저급 알킬설포닐옥시라디칼 또는 아릴설포닐옥시 라디칼을 나타낸다.
  8. 특히 항균제로서 사용되기 위한, 제1항 내지 제5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물 또는 치료학상 허용가능한 그의 염.
  9. 허용가능한 제약학적 보조물외에 제1항 내지 제5항중 어느 한항에 따른 한가지 이상의 일반식(Ⅰ)의 화합물 또는 생리학상 허용가능한 그의 염을 함유하는 것을 특징으로 하는 제약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880017747A 1987-12-29 1988-12-29 7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산의 유도체 및 그의 제조방법 KR920004136B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8718289A FR2625200A1 (en) 1987-12-29 1987-12-29 7-(1-Azetidinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and their application as medicaments
FR8718289 1988-07-20
FR888809816A FR2634483B2 (fr) 1987-12-29 1988-07-20 Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments
FR8809816 1988-07-20

Publications (2)

Publication Number Publication Date
KR890009911A true KR890009911A (ko) 1989-08-04
KR920004136B1 KR920004136B1 (ko) 1992-05-25

Family

ID=26226417

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880017747A KR920004136B1 (ko) 1987-12-29 1988-12-29 7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산의 유도체 및 그의 제조방법

Country Status (14)

Country Link
US (1) US4927926A (ko)
EP (1) EP0324298B1 (ko)
JP (1) JPH0813811B2 (ko)
KR (1) KR920004136B1 (ko)
AU (1) AU617735B2 (ko)
DE (1) DE3876969T2 (ko)
DK (1) DK726188A (ko)
ES (1) ES2010114A6 (ko)
FR (1) FR2634483B2 (ko)
GR (1) GR3006664T3 (ko)
HU (1) HU206206B (ko)
NO (1) NO176605C (ko)
PT (1) PT89352B (ko)
YU (1) YU47124B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839355A (en) * 1987-09-09 1989-06-13 Sterling Drug Inc. Tricyclic-pyridinylquinoline compounds, their preparation and use
US5173484A (en) * 1988-02-05 1992-12-22 Bayer Aktiengesellschaft Quinolone- and naphthyridone carboxylic acid derivatives, process for their production, antibacterial compositions and feed additives containing them
DE3814517A1 (de) * 1988-02-05 1989-08-17 Bayer Ag Chinolon- und naphthyridoncarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH0674261B2 (ja) * 1988-06-21 1994-09-21 塩野義製薬株式会社 キノロンカルボン酸誘導体
EP0997466A1 (en) * 1988-10-24 2000-05-03 PROCTER & GAMBLE PHARMACEUTICALS, INC. Novel antimicrobial lactam-quinolones
FR2654728B2 (fr) * 1989-03-16 1994-09-23 Esteve Labor Dr Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicament.
FR2644455B1 (fr) * 1989-03-16 1994-09-23 Esteve Labor Dr Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicaments
FR2649106A2 (fr) * 1989-06-29 1991-01-04 Esteve Labor Dr Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicament
NO177302C (no) * 1989-03-16 1995-08-23 Esteve Labor Dr Analogifremgangsmåte til fremstilling av terapeutisk aktive substituerte azetidinylkinolon(naftyridon)karboksylsyrederivater
IE912902A1 (en) * 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
FR2676445B1 (fr) * 1991-05-16 1995-02-03 Esteve Labor Dr Derives de pyridone amino acide azetidinyl substitues, leur preparation et leur application en tant que medicaments.
US5556861A (en) * 1991-10-01 1996-09-17 Laboratoire Roger Bellon 1,8 benzonaphthyridine derivatives and antimicrobial compositions
FR2690161B1 (fr) * 1992-04-16 1995-06-30 Esteve Labor Dr Derives de pyridone azetidinyl substitues avec activite antimicrobienne.
FR2692577B1 (fr) * 1992-05-26 1996-02-02 Bouchara Sa Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
JP2005097116A (ja) * 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
WO2005026146A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Azetidinyl quinolones as antibacterial agents
ATE484509T1 (de) * 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
WO2014062667A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
AU2014334619A1 (en) * 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
ES2742843T3 (es) * 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
CN113045539B (zh) * 2021-03-30 2021-12-07 苏州大学 2-(4,4-二氯-1-(8-喹啉基)-2-氮杂环丁基)羧酸酯衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4540690A (en) * 1982-02-09 1985-09-10 The Upjohn Company 2-(Phenylmethylene)cycloalkylamines and -azetidines
US4777175A (en) * 1982-09-09 1988-10-11 Warner-Lambert Company Antibacterial agents
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
US4665079A (en) * 1984-02-17 1987-05-12 Warner-Lambert Company Antibacterial agents
JPS6089480A (ja) * 1983-10-21 1985-05-20 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体
JPS60126284A (ja) * 1983-12-09 1985-07-05 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体およびその塩
CA1267413A (en) * 1984-04-26 1990-04-03 Abbott Laboratories Quino-benoxazine antibacterial compounds
US4588263A (en) * 1984-05-02 1986-05-13 International Business Machines Corporation An adjustable-optical prism with integral-polarizing beam splitter and applications thereof
JPS61137885A (ja) * 1984-12-08 1986-06-25 Dainippon Pharmaceut Co Ltd １，８−ナフチリジン誘導体、そのエステルおよびその塩
US4617308A (en) * 1985-01-25 1986-10-14 Warner-Lambert Company 7-substituted amino-1-aryl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and derivatives thereof as antibacterial agents
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
WO1989003828A1 (en) * 1987-10-26 1989-05-05 Pfizer Inc. Azetidinyl quinolone carboxylic acids and esters
AU603936B2 (en) * 1988-02-04 1990-11-29 Chenault D. Lee Disposable vaginal speculum

Also Published As

Publication number Publication date
NO176605B (no) 1995-01-23
HU206206B (en) 1992-09-28
NO176605C (no) 1995-05-03
FR2634483B2 (fr) 1994-03-04
EP0324298A1 (fr) 1989-07-19
PT89352B (pt) 1993-09-30
NO885797L (no) 1989-06-30
DK726188A (da) 1989-06-30
YU237088A (en) 1990-12-31
NO885797D0 (no) 1988-12-28
DE3876969T2 (de) 1993-05-19
HUT50467A (en) 1990-02-28
ES2010114A6 (es) 1989-10-16
US4927926A (en) 1990-05-22
YU47124B (sh) 1994-12-28
KR920004136B1 (ko) 1992-05-25
JPH01301677A (ja) 1989-12-05
DE3876969D1 (de) 1993-02-04
FR2634483A2 (fr) 1990-01-26
AU2757888A (en) 1989-06-29
GR3006664T3 (ko) 1993-06-30
EP0324298B1 (fr) 1992-12-23
AU617735B2 (en) 1991-12-05
JPH0813811B2 (ja) 1996-02-14
DK726188D0 (da) 1988-12-28
PT89352A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
KR890009911A (ko) 7-(1-아제티디닐)-1,4-디히드로-4-옥소-3-퀴놀린 카르복실산의 유도체, 그의 제조방법 및 제약학적 조성물
KR930000503A (ko) 7-이소인돌리닐-퀴놀론- 및 -나프티리돈카르복실산 유도체
KR880012593A (ko) 5-치환 퀴놀론- 및 나프티리돈 카르복실산 유도체
KR940000368B1 (ko) 신규 퀴놀린 카르본산 유도체
KR870008847A (ko) 퀴놀론 카복실산 유도체 및 그의 제조방법
KR850002481A (ko) 6-플루오로-1,4-디히드로-4-옥소-7-치환피페라지닐키놀린-3-카르복실산 유도체 및 그 조법
AU616422B2 (en) 8-trifluoromethyl quinolones as antibacterial agent
CA2395459A1 (en) Use of quinoline and quinolizinone derivatives as chemotherapeutic agents
KR870000329A (ko) 항균적으로 활성인 퀴놀론카르복실산 에스테르의 제조방법
KR880005137A (ko) 항균제-ⅱ
KR930016421A (ko) 퀴놀론- 및 나프티리돈-카르복실산 유도체
IE58333B1 (en) Quinoline antibacterial compounds
KR920000759B1 (ko) 7-(3-아릴-1-피페라지닐)- 및 7-(3-시클로헥실-1-피페라지닐)-3-퀴놀론 카르복실산의 제조방법
JPH03502452A (ja) 抗菌剤
KR840006990A (ko) 1-시클로프로필-6-플루오로-1,4-디하이드로-4-옥소-7-(알킬-1-피페라지닐)퀴놀린-3-카복실산의 제조방법
KR850007596A (ko) 1,4-디하이드로-4-옥소나프티리딘 유도체의 제조방법
KR900003152A (ko) 스피로 화합물
EP0154780B1 (en) Quinoline antibacterial compounds
PT81476A (en) Process for the preparation of quinolone carboxylic acid derivatives
KR970704694A (ko) 항미생물 화합물의 제조방법(process for making antimicrobial compounds)
KR860008163A (ko) 항균제인 퀴놀린-3- 카복실산의 개량된 제법
KR900014379A (ko) 5-치환-1,4-디히드로-4-옥소-나프티리딘-3-카르복실레이트 항균제
KR870007155A (ko) 7-(치환)피페라지닐-1-에틸-6-플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실산 및 그 생성방법
IL63945A0 (en) Substituted quinoline carboxylic acid,metal salts thereof and pharmaceutical compositions containing the same
EP0288519A1 (en) 1-tertiary-alkyl-substituted naphthyridine- and quinoline-carboxylic acid antibacterial agents

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950512

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee